Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873050 · ClinicalTrials.gov registry record · Phase 4
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
A Phase 4 study of PreDiabetes and Postpartum Disorder, sponsored by Woman's.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT04873050: Recruiting Phase 4 study of PreDiabetes and Postpartum Disorder, sponsored by Woman's.
NCT04873050 is a Phase 4 study of PreDiabetes and Postpartum Disorder that is actively recruiting participants, run by Woman's. The registered enrollment target is 102 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04873050, a Phase 4 study of PreDiabetes and Postpartum Disorder, is actively recruiting participants, sponsored by Woman's.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.
Primary Outcome
Glucose tolerance to be determined by glycemic response to a 75 gram, two-hour oral glucose tolerance test (OGTT). Regression to normoglycemia is defined by fasting glucose \<100mg/dL and 120 minute glucose \<140 mg/dL
Conditions Studied
Interventions
- DRUG Semaglutide Pen Injector [Ozempic]
- DRUG Placebo semaglutide pen injector
Study Locations (1)
Louisiana
- Woman's Hospital - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
What NCT04873050 shows while recruiting
NCT04873050 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide Pen Injector [Ozempic] is the first listed.
NCT04873050 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT04873050 about?
NCT04873050 is a clinical study titled "Treatment to Regress to Normoglycemia in Women with a Recent History of GDM". The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabete...
What is the current status of trial NCT04873050?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2022-01-13. Estimated completion is 2026-03-01.
What conditions does trial NCT04873050 study?
This clinical trial studies the following conditions: PreDiabetes, Postpartum Disorder.
What interventions are being tested in trial NCT04873050?
The interventions under investigation include: Semaglutide Pen Injector [Ozempic] (DRUG), Placebo semaglutide pen injector (DRUG).
Who is sponsoring clinical trial NCT04873050?
This trial is sponsored by Woman's, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873050 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04873050's enrollment target sits among peer trials
102 58th of 149 higher than 91 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
RECRUITING · Phase 4
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
ACTIVE NOT RECRUITING · Phase 4
-
Use of Empagliflozin to Treat Prediabetes
ACTIVE NOT RECRUITING · Phase 4
-
Incretins in Impaired Fasting Glucose
COMPLETED · Phase 4
-
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI